Omalizumab or dupilumab suggested for adults with moderate-to-severe allergic asthma, history of exacerbations requiring oral ...

Please provide your email address to receive an email when new articles are posted on . IL-13, which dupilumab blocks, induces nitric oxide production, which leads to mucus hypersecretion. At week 24, ...

TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® ...

Paris and Tarrytown, NY - March 2, 2018 - The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application of Dupixent ® (dupilumab) as an add-on ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Approximately half of patients do not respond to H1 ...

BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Regeneron/Sanofi) for the treatment of eosinophilic esophagitis (EoE) in children aged 1-11 years and weighing ≥ 15 kg. It ...

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

This study enhances current understandings of dupilumab use in patients with atopic dermatitis (AD) by showing its real-world effectiveness and safety. Dupilumab is an effective and safe treatment ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...

The US Food and Drug Administration (FDA) has issued a complete response letter regarding the application for approval of dupilumab for the treatment of chronic spontaneous urticaria (CSU) in people ...